MUDr. Peter Múdry, Ph.D.
Assistant professor, Department of Pediatric Oncology
correspondence Address:
Černopolní 212/9, 662 63 Brno
phone: | +420 532 23 4126, 4614 |
---|---|
e‑mail: |
Total number of publications: 146
2024
-
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
Cancer, year: 2024, DOI
-
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
International journal of cancer, year: 2024, volume: 155, edition: 8, DOI
-
Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome
NPJ PRECISION ONCOLOGY, year: 2024, volume: 8, edition: 1, DOI
2023
-
Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.
Year: 2023, type: Conference abstract
-
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Journal of clinical oncology, year: 2023, volume: 41, edition: 13, DOI
-
Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone
Cancers, year: 2023, volume: 15, edition: 18, DOI
-
Risk factors for tumors or leukemia development in the first two years of life
Biomedical Papers, Olomouc: Palacky University, year: 2023, volume: 167, edition: 2, DOI
-
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Scientific reports, year: 2023, volume: 13, edition: 1, DOI
2022
-
A case report of aneurysmal bone cyst of the proximal ulna treated with allograft resection after neoadjuvant targeted therapy
Year: 2022, type: Conference abstract
-
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JCO PRECISION ONCOLOGY, year: 2022, volume: 6, edition: June 2022, DOI